Pfizer restricts seven drugs for executions. Pfizer stock costs EUR 26.25 at Xetra close

Published on 10/15/2026 at 11:17 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Pfizer limits seven drugs to medical buyers on October 15, 2026. Pfizer stock costs EUR 26.25 on October 15, 2026 versus EUR 26.25 Xetra close.

Pfizer policy and upcoming dates

Pfizer restricted seven products for lethal injections on October 15, 2026.
Second-quarter revenue reached USD 15.03 billion against USD 14.40 billion expected, while adjusted earnings per share came to USD 0.77 against USD 0.68.
Pfizer stock trades at EUR 26.25 at 11:10 a.m. CEST at Lang & Schwarz on October 15, 2026, unchanged versus the Xetra close of October 14, 2026.
Pfizer's next earnings date is November 3, 2026, followed by an October 23, 2026 visit to its Italian plant.

Sanfte Aquarell-Illustration einer Bürotürme-Skyline, Symbolbild für Pfizer Inc. Hauptsitz — Aquarellmalerei der New Yorker Skyline repräsentiert den Firmensitz von Pfizer Inc., ISIN US7170811035, Pharma-Branche, Illustration mit AI erstellt.

Pfizer Inc. (ISIN US7170811035) was trading at EUR 26.25 at Lang & Schwarz on October 15, 2026 at 11:10 a.m. CEST, unchanged versus the Xetra close of October 14, 2026 at EUR 26.25. The company is restricting distribution of seven medicines to prevent their use in lethal injections, Pharmaphorum reported on October 15, 2026.

Distribution policy adds a public issue

Pfizer's policy covers seven products, including propofol, midazolam and potassium chloride. Government purchasers must certify medical use and agree not to resell the medicines to prisons for executions, according to Pharmaphorum.

Three events shape the picture

On October 7, 2026, the FDA expanded TUKYSA's use in HER2-positive metastatic breast cancer, with median progression-free survival of 24.90 months versus 16.30 months in the trial comparison, Yahoo Finance reported. On October 8, 2026, Cantor Fitzgerald raised its Pfizer target from USD 27.00 to USD 28.00 while retaining a neutral rating, according to MarketBeat. The October 15, 2026 distribution policy is the latest event.

What does the 2026 setup mean?

The operating test remains Pfizer's ability to offset patent pressure with new products. In the second quarter of 2026, revenue was USD 15.03 billion versus USD 14.40 billion expected, while adjusted earnings per share were USD 0.77 versus USD 0.68 expected, MarketBeat reported. Pfizer's fiscal 2026 adjusted earnings-per-share guidance is USD 2.80 to USD 3.00.

Next dates include October 23

Pfizer's next earnings conference call is scheduled for November 3, 2026, as listed on the company's website. A visit to the Catania plant is set for October 23, 2026, while further talks on planned staffing changes are scheduled for November 10, 2026, according to Global Banking and Finance Review.

Price stays at the Xetra close

The euro quotation gives investors in Germany a flat snapshot against the prior Xetra session. Pfizer's 52-week range in euros is EUR 20.52 to EUR 26.38 as of October 15, 2026, placing the reference price near the upper end of that range. Pfizer was trading at EUR 26.25 at Lang & Schwarz on October 15, 2026 at 11:10 a.m. CEST, unchanged versus the Xetra close of October 14, 2026 at EUR 26.25. The further course of trading is shown by the continuously updated real-time quote of Pfizer stock.